Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection | Zendy

Seong Mi Moon | Zendy; Hye Yun Park | Zendy; ByeongHo Jeong | Zendy; Kyeongman Jeon | Zendy; SooYoun Lee | Zendy; WonJung Koh | Zendy

Open Access

Effect of Rifampin and Rifabutin on Serum Itraconazole Levels in Patients with Chronic Pulmonary Aspergillosis and Coexisting Nontuberculous Mycobacterial Infection

Author(s) -

Seong Mi Moon,

Hye Yun Park,

ByeongHo Jeong,

Kyeongman Jeon,

SooYoun Lee,

WonJung Koh

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.04075-14

Subject(s) - itraconazole , rifabutin , medicine , gastroenterology , nontuberculous mycobacteria , aspergillosis , rifamycin , concomitant , antibiotics , immunology , microbiology and biotechnology , dermatology , pathology , tuberculosis , mycobacterium , biology , antifungal , clarithromycin , helicobacter pylori

We investigated the effects of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis. Serum itraconazole concentrations were significantly lower in patients who received itraconazole with rifampin (median, 0.1 μg/ml;P < 0.001) or rifabutin (median, 0.34 μg/ml;P < 0.001) than those receiving itraconazole alone (median, 5.92 μg/ml). Concomitant use of rifampin or rifabutin and itraconazole should be avoided in patients with chronic pulmonary aspergillosis and coexisting mycobacterial infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research